Why Ikea is recalling more than 54,000 garlic presses
The recall, published on July 31 by the U.S. Consumer Product Safety Commission (CPSC) includes about 43,830 Ikea garlic presses sold in the U.S. and another 10,700 sold in Canada. Here's what to know about the affected products:
Which garlic press is being recalled?
The product in question is the Ikea 365+ VÄRDEFULL garlic press, used to crush garlic cloves.
The garlic press has a black rubber handle and zinc-coated garlic chamber, and affected models were sold for $8 at Ikea stores nationwide and online at IKEA.com from March 2024 through May 2025. According to the CPSC, only models with the Ikea logo—which can be found at the upper part of the handle—are subject to the recall.
What's happened?
Per an Ikea press release, the garlic presses are being recalled 'Due to a production error, identified after an internal investigation, indicating a risk of small metal pieces detaching during use and subsequently being ingested with food.'
Have any incidents been reported so far?
Unfortunately, yes. The CPSC report notes that Ikea has received a total of 10 incident reports globally, 'including three reports of lacerations and finger splinters.' No incidents or injuries have been reported in the U.S. thus far.
What should I do if I own a recalled garlic press?
If you own the Ikea 365+ VÄRDEFULL, stop using it immediately. The product can be returned to any Ikea location for a full refund, even without proof of purchase.
'Additionally, IKEA encourages customers to spread the word about this recall, especially if they know that the recalled product was offered, lent or sold to someone else,' Ikea's report reads.
For more information, customers are directed to visit IKEA.ca/ProductRecalls or call the company at 1-800-661-9807.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (''2510') anticipated before the end of 2025 Updated '2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025 World Conference on Lung Cancer (WCLC) by ImmuneOnco DALLAS, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ('Instil') (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2025 financial results and provided a corporate update. Recent Highlights: In June, announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer In July, announced the Investigational New Drug (IND) application for '2510 was cleared by the U.S. FDA In July, ImmuneOnco, Instil's collaborator, announced preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of '2510 in combination with chemotherapy for front-line patients with advanced non-small cell lung cancer (NSCLC) conducted in China by ImmuneOnco In August, ImmuneOnco announced that an abstract has been accepted for poster presentation at IASLC's 2025 World Conference on Lung Cancer (September 6th-9th, 2025), which will provide updated results from additional patients with relapsed/refractory squamous-NSCLC treated with '2510 as monotherapy Second Quarter 2025 Financial and Operating Results: As of June 30, 2025, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of $103.6 million, which consisted of $7.7 million in cash and cash equivalents, approximately $0.2 million in restricted cash, $84.1 million in marketable securities, and $11.7 million in long-term investments, compared to $115.1 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2024, consisting of $8.8 million in cash and cash equivalents, $1.8 million in restricted cash, and $104.5 million in marketable securities. Instil expects that its cash, cash equivalents, marketable securities and long-term investments as of June 30, 2025 will enable it to fund its operating plan beyond 2026. In-process research and development expenses were $10.0 million for both the three and six months ended June 30, 2025, compared to nil for both the three and six months ended June 30, 2024. Research and development expenses were $6.7 million and $12.1 million for the three and six months ended June 30, 2025, respectively, compared to $2.9 million and $10.2 million for the three and six months ended June 30, 2024, respectively. General and administrative expenses were $6.2 million and $15.3 million for the three and six months ended June 30, 2025, respectively, compared to $10.7 million and $23.1 million for the three and six months ended June 30, 2024, respectively. Restructuring and impairment charges were $0.5 million and $16.6 million for the three and six months ended June 30, 2025, respectively, compared to $0.5 million and $4.8 million for three and six months ended June 30, 2024, respectively. Net loss per share, basic and diluted were $3.24 and $7.55 for the three and six months ended June 30, 2025, respectively, compared to $2.29 and $6.03 for the three and six months ended June 30, 2024, respectively. Non-GAAP net loss per share, basic and diluted, were $2.88 and $4.21 for the three and six months ended June 30, 2025, respectively, compared to $1.57 and $3.95 for the three and six months ended June 30, 2024, respectively. Note Regarding Use of Non-GAAP Financial Measures In this press release, Instil has presented certain financial information that has not been prepared in accordance with U.S. generally accepted accounting principles ('GAAP'). These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share, which are defined as net loss and net loss per share, respectively, excluding non-cash stock-based compensation expense and restructuring and impairment charges. Instil believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Instil's financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Instil's operating results. In addition, these non-GAAP financial measures are among the indicators Instil's management uses for planning purposes and to measure Instil's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Instil may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures. About Instil Bio Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors. For more information visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'expects,' 'exploring,' 'future,' 'intends,' 'may,' 'plans,' 'potential,' 'projects,' 'targets' and 'will' or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements regarding our expectations with respect to the therapeutic potential of AXN-2510/IMM2510, clinical development of AXN-2510/IMM2510, including the initiation of clinical trials for AXN-2510/IMM2510 and the generation and presentation of clinical data for AXN-2510/IMM2510 and the timing thereof; research, development, regulatory and clinical plans for AXN-2510/IMM2510; Instil's expectations regarding its capital position, resources, and balance sheet, including its cash runway; and other statements that are not historical fact. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties associated with the costly and time-consuming drug product development process and the uncertainty of clinical success; the risks inherent in relying on collaborators and other third parties, including for manufacturing and generating clinical data, and the ability to rely on any such data from clinical trials in China in regulatory filings submitted to regulatory authorities outside of China; the risks and uncertainties related to successfully making regulatory submissions and initiating, enrolling, completing and reporting data from clinical trials, particularly collaborator-led clinical trials, as well as the risks that results obtained in any clinical trials to date may not be indicative of results obtained in ongoing or future trials and that product candidates may otherwise not be effective treatments in their planned indications; risks related to macroeconomic conditions, including as a result of international conflicts and U.S.-China trade and political tensions, as well as interest rates, inflation, tariffs and other factors, which could materially and adversely affect our business and operations and those of our collaborators; the risks and uncertainties associated with the time-consuming and uncertain regulatory approval process and the sufficiency of Instil's cash resources; and other risks and uncertainties affecting Instil's plans and development programs, including those discussed in the section titled 'Risk Factors' in Instil's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 to be filed with the SEC, as well as Instil's other filings with the SEC. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law. Contacts: Investor Relations:1-972-499-3350 investorrelations@ INSTIL BIO, FINANCIAL DATA (Unaudited; in thousands, except share and per share amounts) Selected Condensed Consolidated Balance Sheet Data June 30, 2025 December 31, 2024 Cash, cash equivalents, restricted cash, marketablesecurities and long-term investments $ 103,632 $ 115,145 Total assets $ 230,986 $ 263,567 Total liabilities $ 99,316 $ 94,131 Total stockholders' equity $ 131,670 $ 169,436 Condensed Consolidated Statements of Operations Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Operating expenses: In-process research and development $ 10,000 $ — $ 10,000 $ — Research and development 6,743 2,921 12,114 10,177 General and administrative 6,157 10,706 15,266 23,130 Restructuring and impairment charges 540 508 16,622 4,783 Total operating expenses 23,440 14,135 54,002 38,090 Loss from operations (23,440 ) (14,135 ) (54,002 ) (38,090 ) Interest income 1,044 1,919 2,219 3,981 Interest expense (1,582 ) (1,999 ) (2,680 ) (3,980 ) Other rental income 2,242 — 4,484 — Other income (expense), net 342 (702 ) 385 (1,130 ) Net loss $ (21,394 ) $ (14,917 ) $ (49,594 ) $ (39,219 ) Net loss per share, basic and diluted $ (3.24 ) $ (2.29 ) $ (7.55 ) $ (6.03 ) Weighted-average shares used incomputing net loss per share, basic anddiluted 6,596,975 6,503,913 6,564,994 6,503,913 INSTIL BIO, of GAAP to Non-GAAP Net Loss and Net Loss per Share (Unaudited; in thousands, except share and per share amounts) Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Net loss $ (21,394 ) $ (14,917 ) $ (49,594 ) $ (39,219 ) Adjustments: Non-cash stock-based compensationexpense 1,824 4,173 5,319 8,688 Restructuring and impairmentcharges 540 508 16,622 4,783 Non-GAAP net loss $ (19,030 ) $ (10,236 ) $ (27,653 ) $ (25,748 ) Net loss per share, basic and diluted $ (3.24 ) $ (2.29 ) $ (7.55 ) $ (6.03 ) Adjustments: Non-cash stock-based compensationexpense per share 0.28 0.64 0.81 1.34 Restructuring and impairmentcharges per share 0.08 0.08 2.53 0.74 Non-GAAP net loss per share, basicand diluted* $ (2.88 ) $ (1.57 ) $ (4.21 ) $ (3.95 ) Weighted-average shares outstanding,basic and diluted 6,596,975 6,503,913 6,564,994 6,503,913 * Non-GAAP net loss per share, basic and diluted may not total due to in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
18 minutes ago
- Associated Press
'Nursing Ratios Save Lives:' New Study Recommends Ontario Government Mandate Safe Nurse Staffing Levels in Hospitals
OTTAWA, Ontario--(BUSINESS WIRE)--Aug 13, 2025-- A new academic study says implementing nurse-to-patient ratios in Ontario's hospitals would save lives, improve overall patient care and help address a long-standing staffing crisis. Nurse-patient ratios: saving lives and rebuilding nurses' morale has been co-authored by Dr. Margaret Keith and Dr. Jim Brophy, who since 2017 have produced four studies on working conditions in Ontario's health care system. The study was commissioned by the Ontario Council of Hospital Unions – the hospital division of the Canadian Union of Public Employees (OCHU-CUPE), which represents nearly 50,000 staff. 'The evidence shows that nurse-patient ratios save lives,' said Dr. Brophy, a researcher affiliated with the University of Windsor. 'Assigning nurses a manageable workload ensures patients receive appropriate care, which in a high-stakes hospital environment can mean the difference between life and death.' Dr. Brophy will present the findings at a press conference in Ottawa on Thursday at 10 a.m. He will be joined by Michael Hurley, president of OCHU-CUPE, and Rachel Fleming, a registered practical nurse represented by the union. The study is based on existing research on staffing levels in hospitals, and in-depth interview examination of nurse staffing standards in places like California, British Columbia, Nova Scotia and two provinces in Australia. :gv/cope491 View source version on CONTACT: For more information, contact: Zee Noorsumar CUPE Communications [email protected] 647-995-9859 KEYWORD: NORTH AMERICA CANADA INDUSTRY KEYWORD: NURSING LABOR ADVOCACY GROUP OPINION HOSPITALS PUBLIC POLICY/GOVERNMENT HEALTH STATE/LOCAL PUBLIC POLICY OTHER POLICY ISSUES SOURCE: Canadian Union of Public Employees Copyright Business Wire 2025. PUB: 08/13/2025 06:15 AM/DISC: 08/13/2025 06:15 AM
Yahoo
an hour ago
- Yahoo
How good are the school lunches in Rhode Island? Pretty good, report says. See ranking
School in Rhode Island will be starting soon, which means another year of school lunches. As a parent, you're not exactly there with your children to assess the cafeteria food's quality, but you would hope the school lunches are at least healthy and nutritious for the kids there. It would be nice to know for sure, though. In Rhode Island, a recent report found the odds of your child having a healthy lunch are pretty good. ProCare Therapy released the State of School Lunch Report, ranking which states in the U.S. have the healthiest school lunches and which states are lacking in that department, and ranked Rhode Island No. 8 in the U.S. The report took into account participation in the Farm to School program, which includes activities for school gardens and farms so that children can learn about where their food comes from, and other programs. How healthy are Rhode Island school meals With a score of 62.38, Rhode Island was ranked No. 8 out of the 50 states and Washington, D.C., included in the report's list. With this ranking, the Ocean State is one of the most dedicated places in the country toward providing healthy school meals to children, the report said. Vermont took the top spot. "Hawaii also leads in the percentage of schools serving local foods, with Virginia, Washington D.C., Rhode Island, and Oregon following suit, where over 87% of schools provide locally grown food to their students," the report said. The top 10 places in the U.S. for healthiest school meals in the report are: Vermont Hawaii Washington, D.C. West Virginia Delaware Virginia Oregon Rhode Island New York Alaska More: Are the feds coming for coffee milk in schools? They might not even find it on the menu. Here's what you need to know about free lunches in Rhode Island. Are school lunches free in Rhode Island You can apply for free or reduced-price school lunches for your children in Rhode Island, according to the state government website. "The cost of breakfast and lunch varies by school, but regardless of the cost, your children may qualify for free meals or for reduced-price meals," the website said. Rin Velasco is a trending reporter. She can be reached at rvelasco@ This article originally appeared on The Providence Journal: RI ranks No. 8 in healthy school lunches in the U.S., report says Solve the daily Crossword
